HyACT Chemotherapy

HyACT®- delivering more drug to the tumour, leading to improved treatment of cancer.

HA-Doxorubicin (Hyaluronic acid + doxorubicin)

Doxorubicin remains one of the most widely prescribed chemotherapy agents, but 26% of patients who receive a cumulative dose of doxorubicin of 550 mg/m2 will experience cardiotoxicity leading to heart failure.

HA-Doxorubicin successfully completed a Phase I / IIa clinical trial in patients with metastatic cancers. The Phase I/IIa clinical trial was conducted in 16 patients with metastatic, drug resistant disease (lung, prostate, breast cancers, sarcoma and adenocarcinoma of unknown primary origin) with a life expectancy of at least 12 weeks. Patients were treated using a formulation that contained 500 mg HA and a standard dose of doxorubicin of 60 mg/m2.

  • No unexpected toxicity was observed demonstrating the ability to safely combine HA with a clinically active dose of doxorubicin;
  • 4 of 16 patients treated with HA-Doxorubicin had a partial tumour response; and
  • 3 of 16 patients treated with HA-Doxorubicin recorded stable disease.

HA-5-Fluorouracil (hyaluronic acid + 5-fluorouracil)

5-Fluorouracil is a mainstay of first line therapy for colorectal cancer. However, almost a third of patients who receive 5-fluorouracil require hospital treatment for toxicity effects.

HA-5-Fluorouracil successfully completed a Phase I / IIa clinical trial in patients with metastatic colorectal cancer. The trial was conducted in 14 patients with metastatic colorectal cancer. Patients were treated using a formulation that contained 500 mg HA and 450 mg/m2/day of 5-Fluorouracil.

  • No unexpected toxicity was observed;
  • 3 of 9 patients treated with HA-5-Fluorouracil without folinic acid recorded stable disease; and
  • 2 of 4 patients treated with HA-5-Fluorouracil with folinic acid recorded stable disease.